BACKGROUND: The purpose of this analysis was to compare disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) between pregnant and nonpregnant patients with breast cancer. METHODS: From 1989 to 2009, 75 women were treated with chemotherapy during pregnancy. Each pregnant case was matched on age and cancer stage to two nonpregnant patients with breast cancer (controls). Fisher's exact test, the Kaplan-Meier method, and Cox proportional hazards regression models were used. RESULTS: Median follow-up time for patients who were alive at the end of follow-up (n = 159) was 4.20 years (range: 0.28-19.94 years). DFS at 5 years was 72% (95% confidence interval [CI]: 58.3%-82.1%) for pregnant patients and 57% (95% CI: 46.7%-65.8%) for controls (p = .0115). Five-year PFS was 70% (95% CI: 56.8%-80.3%) for pregnant patients and 59% (95% CI: 49.1%-67.5%) for controls (p = .0252). Five-year OS was 77% (95% CI: 63.9%-86.4%) for pregnant patients and 71% (95% CI: 61.1%-78.3%) for controls (p = .0461). Hazard ratio estimates favored improved survival for pregnant patients in univariate analyses and multivariate analyses, controlling for age, year of diagnosis, stage, and tumor grade. CONCLUSIONS: For patients who received chemotherapy during pregnancy, survival was comparable to-if not better than-that of nonpregnant women. Pregnant patients with breast cancer should receive appropriate local and systemic therapy for breast cancer.
BACKGROUND: The purpose of this analysis was to compare disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) between pregnant and nonpregnant patients with breast cancer. METHODS: From 1989 to 2009, 75 women were treated with chemotherapy during pregnancy. Each pregnant case was matched on age and cancer stage to two nonpregnant patients with breast cancer (controls). Fisher's exact test, the Kaplan-Meier method, and Cox proportional hazards regression models were used. RESULTS: Median follow-up time for patients who were alive at the end of follow-up (n = 159) was 4.20 years (range: 0.28-19.94 years). DFS at 5 years was 72% (95% confidence interval [CI]: 58.3%-82.1%) for pregnant patients and 57% (95% CI: 46.7%-65.8%) for controls (p = .0115). Five-year PFS was 70% (95% CI: 56.8%-80.3%) for pregnant patients and 59% (95% CI: 49.1%-67.5%) for controls (p = .0252). Five-year OS was 77% (95% CI: 63.9%-86.4%) for pregnant patients and 71% (95% CI: 61.1%-78.3%) for controls (p = .0461). Hazard ratio estimates favored improved survival for pregnant patients in univariate analyses and multivariate analyses, controlling for age, year of diagnosis, stage, and tumor grade. CONCLUSIONS: For patients who received chemotherapy during pregnancy, survival was comparable to-if not better than-that of nonpregnant women. Pregnant patients with breast cancer should receive appropriate local and systemic therapy for breast cancer.
Authors: P Bonnier; S Romain; J M Dilhuydy; F Bonichon; J P Julien; C Charpin; C Lejeune; P M Martin; L Piana Journal: Int J Cancer Date: 1997-09-04 Impact factor: 7.396
Authors: Karin M E Hahn; Peter H Johnson; Nancy Gordon; Henry Kuerer; Lavinia Middleton; Mildred Ramirez; Wei Yang; George Perkins; Gabriel N Hortobagyi; Richard L Theriault Journal: Cancer Date: 2006-09-15 Impact factor: 6.860
Authors: D L Berry; R L Theriault; F A Holmes; V M Parisi; D J Booser; S E Singletary; A U Buzdar; G N Hortobagyi Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: Ciara C O'Sullivan; Sheeba Irshad; Zheyu Wang; Zhuojun Tang; Christopher Umbricht; Gary L Rosner; Mindy S Christianson; Vered Stearns; Karen Lisa Smith Journal: Breast Cancer Res Treat Date: 2020-03-11 Impact factor: 4.872
Authors: Katarzyna J Jerzak; Nechama Lipton; Sharon Nofech-Mozes; Dina Boles; Elzbieta Slodkowska; Gregory R Pond; Ellen Warner Journal: Breast Cancer Res Treat Date: 2021-07-27 Impact factor: 4.872
Authors: Rashmi K Murthy; Richard L Theriault; Chad M Barnett; Silvia Hodge; Mildred M Ramirez; Andrea Milbourne; Sue A Rimes; Gabriel N Hortobagyi; Vicente Valero; Jennifer K Litton Journal: Breast Cancer Res Date: 2014-12-30 Impact factor: 6.466